Meningitis Diagnostic Testing Market Size & Share 2024 – 2032

Meningitis Diagnostic Testing Market Size

The global meningitis diagnostic testing market size was valued at USD 119.5 million in 2023 and is expected to exhibit growth at a CAGR of 3.5% from 2024 to 2034. The expansion of the market appears to be dependent on many market drivers such as the increase in occurrence of meningitis cases or global promotions and development of new technologies as well as new treatment options.

For instance, the National Centre for Biotechnology Information (NCBI) estimates that meningitis caused 236,222 deaths and loss of 15,649,865 Years of Life (YLL) globally in 2019. Such a figure is alarming and underscores the necessity for valid measures to be adopted and to control the situation under consideration.
 

The increased demand for early and precise diagnosis has further caused demand for new improvements in diagnostic testing methods such as the polymerase chain reaction (PCR) assay and the next-generation sequencing (NGS). Furthermore, such drugs as antibiotics, corticosteroids, and vaccines under design to improve outcomes in patients with such meningitis are driving up the demand in this marketplace. Health promotions and educational programs facilitating the improvement of the current situation with meningitis diagnosis and treatment also contribute substantially to the growth of the market. Thus, these reasons together with active studies aimed at inventing vaccines and more accurate diagnostic tests fuel the growth of the meningitis diagnostic testing market.
 

Meningitis diagnostic testing refers to a range of laboratory tests and procedures that are utilized to measure the presence of meningitis, which is in essence an inflammation of the membranous covering of the brain and spinal cord. The tests seek to ascertain the different forms of meningitis that are to be either bacterial or viral or fungal or even parasitic, and alternatively infections from autoimmune disorders.

Meningitis Diagnostic Testing Market Trends

A key factor facilitating the growth of the market is the increase in technological advancements in molecular diagnostics. These inventions constitute improvements in the speed, accuracy, and sensitivity of diagnostic processes.
 

• Old techniques such as blood culture tests are not only time-consuming but also have a low sensitivity. Newer molecular techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), allow for the fast detection of pathogens, which can include causes of meningitis such as bacteria, viruses, and fungi. This ability reduces the time required to administer and receive a diagnosis and improves the chances of the patient receiving appropriate treatment.
   
• Moreover, development of point-of-care (POC) molecular tests allows patients to immediately receive their results during their appointments which improves the decision being made during the appointment and helps in reducing the amount of time a person is hospitalized.
   
• Thus, the gradual change in the expectations of patients to receive fast and accurate diagnostic results will aid in the growth of the markets.
   

Meningitis Diagnostic Testing Market Analysis

Based on test type, the market is segmented into latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and other test types. The PCR assay segment dominated the market with USD 42.2 million in 2023.
 

• PCR assay is the dominant segment in the market due to its accuracy, sensitivity, and speed.
   
• It is possible to use PCR assays to isolate templates of bacterial, viral, or fungal pathogens directly from cerebrospinal fluid (CSF) samples, making it one of the most useful constructs for early diagnostics in the world of science.
   
• In addition, the PCR's efficiency enables medical professionals to arrive at decisions in seconds rather than hours. This sort of speed and assurance is beneficial when treating cases of bacterial meningitis because early intervention is often beneficial, increasing the market size.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on age group, the meningitis diagnostic testing market is divided into infants, children, adolescents, young adults, and adults. The infants segment accounted for significant market share of 39.4% in 2023.
 

• The infant population is the most afflicted by meningitis, and therefore neglecting this segment is detrimental in every sense. Neonates are especially at risk of developing neurological infection such as bacterial meningitis which is caused by group A and B streptococcus and E. coli and Neisseria meningitidis and hence need to be diagnosed and treated without delay.
   
• For instance, according to the National Institutes of Health (NIH), infants under 1 year of age have the highest incidence of bacterial meningitis in the U.S., with an estimated rate of 2.74 cases per 100,000 in this group.
   
• The diagnostic approach in this segment often includes blood cultures and PCR tests, highlighting rapid and sensitive testing methods to minimize complications.
   
• The growing awareness of neonatal infections, as well as providing enhanced diagnostic technologies and healthcare sources, help the market in concentrating on this sector, which in turn promotes development of more effective and non-invasive diagnostic tools to be used for detection purposes.
   

Based on end use, the meningitis diagnostic testing market is divided into hospitals, diagnostic centers, and other end users. The hospitals segment dominated the market with USD 72.8 million in 2023.
 

• The hospital segment is driven by surge in diagnostic tests. Because of their holistic facilities to treat and manage patients emerging with signs and symptoms of meningitis, hospitals are the first-line health facilities to use special diagnostic strategies to provide care in cases of meningitis.
   
• Moreover, the hospitals employ several other methods of diagnosis such as PCR assays, latex agglutination tests, and culture tests to ensure the correct and timely detection of the meningitis pathogens. Due to their rapid clinic absolute sensitivity, PCR assays are widely used at the wards in most hospitals.
   
• In addition, the market is benefitting from the growth of regions where hospitals can perform ELISA and lateral flow assays alongside other complex tests.
   

North America meningitis diagnostic testing market is expected to grow at 3.3% CAGR, to reach USD 73.7 million by the end of 2032.
 

• The market in the U.S. is driven by the presence of greater healthcare awareness regarding meningitis, growth in the healthcare expenditure per capita, and the availability of better infrastructure.
   
• In addition, government initiatives such as immunization and advanced diagnostics enhance the rise in cases of meningitis and propel the U.S. market.
   
• Also, the market is bolstered by the investments in research and development activities in the U.S. market.
   

The UK meningitis diagnostic testing market is experiencing robust growth in Europe market.
 

• The UK market for meningitis diagnostic testing is highly regulated by the government, mainly in healthcare practices, has competition in new technology, and high public awareness.
   
• In addition to this, diagnostic tests such as PCR and blood cultures are much in demand because the National Health Service gets involved with early diagnosis and treatment of meningitis.
   
• Government campaigns promoting vaccination have also contributed to controlling the spread of the disease, so propelling the growth of the market.
   

The Asia Pacific meningitis diagnostic testing market is witnessing substantial growth of 3.8% during the analysis period.
 

• The Asia Pacific market is expanding due to a growing population, increasing healthcare investments, and rising awareness.
   
• Countries like China, India, and Japan are experiencing a rise in demand for rapid diagnostic tools, particularly PCR-based tests and antigen detection methods. Furthermore, government initiatives for disease prevention and vaccination are promoting market growth.
   

Meningitis Diagnostic Testing Market Share

The market is extremely competitive and has constant technology advancement and innovation. A major part of the market is held by renowned top drug manufacturers due to their wide range of advanced diagnostic tools and techniques and treatment drugs. Also, mergers, acquisitions, and collaborations are among the strategic activities that consolidate the position of key players in the market and provide them with the ability to broaden the range of products in the existing and new markets.
 

Meningitis Diagnostic Testing Market Companies

Prominent players operating in the meningitis diagnostic testing industry include:

• Abbott Laboratories
• Becton, Dickinson and Company
• Biomerieux
• Bio-Rad Laboratories
• Certest Biotec
• ELITechGroup
• F. Hoffmann-La Roche
• IMMY
• Seegene
• Siemens Healthineers
• Thermo Fisher Scientific
• Uniogen
   
• Comprehensive portfolio of molecular and immunoassay diagnostic solutions
   
• Extensive global distribution network for reliable test accessibility
   
• Integration of advanced automation to enhance operational efficiency
   
• Broad collaborations with healthcare providers for tailored diagnostic solutions
   

Meningitis Diagnostic Testing Industry News:

• In May 2024, Seegene and Springer Nature have formed a strategic partnership to advance research in disease fields using PCR diagnostic technology. This collaboration is expected to benefit the market by promoting innovation and enhancing diagnostic accuracy.
   

• In February 2024, Siemens Healthineers and Unilabs formed a strategic partnership to enhance diagnostic testing infrastructure. This collaboration improved the diagnostic accuracy and patient outcomes in meningitis and related conditions.
   

The meningitis diagnostic testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Latex agglutination tests
• Lateral flow assay
• PCR assay
• ELISA tests
• Culture test
• Other test types

Market, By Age Group

• Infants
• Children
• Adolescents
• Young adults
• Adults

Market, By End Use

• Hospitals
• Diagnostic centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE